About
About ERYTECH Pharma S.A
PHAXIAM Therapeutics S.A., a biopharmaceutical company, focuses on developing treatments for resistant bacterial infections in France and the United States. It develops eryaspase, which is in Phase 3 clinical development for the treatment of second-line pancreatic cancer, and in Phase 2 stage for the treatment of triple-negative breast cancer and second-line acute lymphoblastic leukemia patients. The company also engages in developing erymethionase, a preclinical product candidate that consists of methionine-"-lyase in red blood cells to target the amino acid metabolism of cancer cells and induce tumor starvation. The company was formerly known as ERYTECH Pharma S.A. and changed its name to PHAXIAM Therapeutics S.A. in June 2023. PHAXIAM Therapeutics S.A. was incorporated in 2004 and is headquartered in Lyon, France.
Visit company website
5 years, 4 months ago
ERYTECH Pharma S.A is currently in a long term downtrend where the price is trading 38.7% below its 200 day moving average.
From a valuation standpoint, the stock is 100.0% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 0.0.
ERYTECH Pharma S.A's total revenue sank by nan% to $0 since the same quarter in the previous year.
Its net income has dropped by 1.8% to $-20M since the same quarter in the previous year.
Finally, its free cash flow fell by 103.9% to $-15M since the same quarter in the previous year.
Based on the above factors, ERYTECH Pharma S.A gets an overall score of 1/5.